ABSTRACT
INTRODUCTION
corresponding to m/z 973.2 was never observed. The lipid A from the OctC4 induced isolates was 145 substantially different from the Pmx-R isolates and similar to the WT profile, with a major peak 146 of the hydroxymyristate derivative and a significant 5-fold increase in representation of 147 palmitoylation (Fig. 3B , see Fig. S4 in the supplemental material). The Ara4N modification was 148 enhanced compared to WT, but not to the extent seen with Pmx-R isolates.
149
Plasmid loss associated with OctC4 resistance. To ascertain the genetic basis for resistance and 150 subsequent phenotypic traits, four day 20 replicates were selected from each treatment group.
151
Clonal expansion of genomic variations were monitored by selecting four colonies per replicate.
152
Additionally, two colonies from the initial isolate were sequenced. The initial isolate harbored 153 multiple acquired resistance genes targeting aminoglycosides, β-lactams, fosfomycin, quinolones, 154 sulfonamides, tetracycline and trimethoprim, consistent with the parent XDR profile (Table 2) .
155
Five plasmid replicons were identified including ColRNAI, IncFIB(K)-Kpn3, IncFII(K), IncN and 156 IncX3. In cross-resistance studies, the only Pmx-R replicate with an alteration in MIC profile to resistance whilst phospholipid transport associated with OctC4 resistance. Genomic 169 alterations identified in polymyxin and OctC4 treated replicates differed significantly. In replicates, genes predominantly associated with LPS processing and lipid A modifications were 171 altered, including crrB, hepIII, lptC, mgrB, pmrB, phoPQ and yciM (Table 3 ). An additional TCS (Fig. 4E) . Alterations in CrrB (D57V), PhoP (R81C) and QseC (S8R, 181 I283L) were confirmed to cause resistance once these genes were introduced into the initial strain 182 (Fig. 4M ). Subtle increases in polymyxin MIC was detected for PhoQ (P420A, G434C), PhoQ 183 (D417N) and QseC (L40F) but did not surpass the breakpoint (Fig. 4M) . This confirms the 184 presence of multiple resistance conferring mutations being present in a single isolate and several 185 contributing to the elevation of MIC.
186
The OctC4 replicates harbored changes in mlaDF, pqiB and traH in all four colonies. Additional 187 genes altered that were apparent in two colonies per replicate included azoR, hinT and rpsA. Strikingly, mlaF (A165P) was impacted in three different OctC4 replicates at the same position 10 induced replicates reduced the MIC by 2-fold, however, consistently only partial growth was 191 observed at 8 µg/ml. This finding validates the partial contribution of these genes to resistance
192
( Fig. 4I-L) . Introduction of WT genes into the initial isolate revealed that the vector and gene did 193 not influence the MIC and confirmed that these alterations are responsible for the resistance 194 observed ( Fig. 4M and N) .
195
Polymyxin unfortunately now induce high levels of resistance during therapeutic use, which is 197 further compromised by suboptimal exposure in the clinic due to the risk of nephrotoxicity (29).
198
Resistance in K. pneumoniae appears to be stable and incurs a minimal fitness cost (30, 31). These 199 clinical characteristics were reflected in our study whereby once the isolate could tolerate 0. 
205
Following 20 days of increasing sub-lethal antibiotic exposure, no cross-resistance was apparent 206 between polymyxins and OctC4. CST and PMB resulted in similar profiles with the only deviation 207 seen in sample PMB_2 in which susceptibility to meropenem was regained. This is due to the 208 absence of blaKPC-2 and blaOXA-9. Additionally, the homogenous loss of the IncX3 plasmid was 209 identified. Clinically, meropenem is being used in combination with polymyxins, and these results
210
suggest that, in some cases, meropenem may overcome polymyxin resistance (32, 33 commonly observed in the clinic. Additional mutations were also identified in phoPQ 231 accompanying the mgrB disruption, which was also apparent in this study (CST_3, CST_4, 232 PMB_2). Other mutations in crrB, mgrB, pmrB, phoPQ and yciM in acquisition of polymyxin 233 resistance have previously been described in resistant strains (16, 17, 38) . Taken together, this isolates, mutations were present in multiple genes within a replicate. CST_3 harbored a deleterious 241 mutation in mgrB (M1I) and additional alterations in phoQ (P420A, G434C) increased tolerance 242 to CST. This was also the circumstance for CST_4 (mgrB: N42I, phoQ: D417N). PMB_2 243 possessed a resistance conferring mutation in mgrB (W47L) and phoP (R81C). The notion that 244 one alteration in TCS drives resistance, the circumstance for the majority of clinical isolates is well 245 accepted (39). However, our findings contradict this concept.
246
We also identified alterations in another TCS, QseBC, which is known to facilitate cross-talk with
247
PmrAB in Escherichia coli (40). In E. coli, PmrB acts as a noncognate partner to the QseBC TCS 248 and has the capability to not only phosphorylate PmrA, but also QseB. The absence of QseC was
249
shown to impact virulence due to the accumulation of phosphorylated QseB and in particular, 250 alterations in the histidine kinase domain attenuates its ability to de-phosphorylate QseB (40, 41).
251
Furthermore, the deletion of qseC and pmrA, promoting phosphorylation of QseB by PmrB, 252 stimulated tolerance to PMB (42). This signalling pathway remains severely under characterized 253 in K. pneumoniae. We observed partial tolerance to PMB when a frameshift mutation was apparent 254 at nucleotide 118; however, full resistance in PMB_4 was promoted by alterations in mgrB (D29Y) 255 and yciM (V43G), which has recently been identified to cause resistance (38). Conversely, PMB_3 256 also harbored a frameshift mutation early in the coding sequence of qseC 257 (GCCTGAGCCTGC17Δ fs ), although an additional I283L change in the histidine kinase region 258 resulted in an MIC of 4 µg/ml. This did not explain the full resistance profile exhibited by PMB_3 259 and due to the presence of both alleles during complementation, the true extent of resistance cannot 260 be deduced. Considering PMB_3 still resulted in the addition of Ara4N to lipid A, we speculate 261 that due to the perturbation in the QseC kinase, this is increasing the accumulation of Table S1 in the supplemental material). Clinical breakpoints were determined in 
349
Complementation assays. Genes speculated to cause resistance underwent complementation as 350 previously described (61). Briefly, genes harboring a potential variation contributing to resistance 351 was amplified using the 2X Phusion HF master mix (ThermoFisher) with primers listed in Table   352 S2 in the supplemental material. The gene was cloned into the pCR-BluntII-TOPO using the Zero upstream and fs represents a frameshift mutation.
721
c The introduction of a truncation in the protein downstream of the alteration is noted as tr .
